Understanding how a genetic variant affects white blood cell counts in certain populations
Evaluating the clinical implications for ACKR1/DARC associated neutropenia
This study is looking at how a certain gene variation affects white blood cell counts in African Americans, with the goal of helping doctors better diagnose infections and manage chemotherapy for patients with this genetic difference.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11091664 on NIH RePORTER |
What this research studies
This research investigates the impact of a specific genetic variant associated with the Duffy Antigen Receptor Chemokine (DARC/ACKR1) on white blood cell and neutrophil counts, particularly in African American populations. By analyzing how this genetic difference influences blood cell counts, the study aims to improve the accuracy of diagnosing infections and managing chemotherapy in patients with this variant. The research will involve collecting and analyzing blood samples to better understand the clinical implications of these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research include African American individuals and others with African ancestry who may carry the DARC/ACKR1 genetic variant.
Not a fit: Patients who do not have the DARC/ACKR1 genetic variant or those from populations not affected by this genetic difference may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnoses and tailored treatments for patients with the DARC/ACKR1 genetic variant, improving their overall healthcare outcomes.
How similar studies have performed: Previous research has identified the genetic variant's effects, but this study aims to translate those findings into clinical practice, making it a novel approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Ziv, Elad — University of California, San Francisco
- Study coordinator: Ziv, Elad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.